Cortex Study Center
- Address
- lock Available on a paid plan
Cortex Study Center - Cardiovascular Disease Prevention
Cortex Study Center is a leading research facility specializing in cardiovascular disease prevention and innovative therapeutic interventions. The center focuses on advancing primary prevention strategies for patients at high risk of developing cardiovascular complications, with particular expertise in lipid-lowering therapies and their impact on long-term cardiovascular outcomes.
- Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
- Major adverse cardiovascular events (MACE) risk reduction studies
- Novel lipid-lowering therapeutic agents including inclisiran
The center conducts rigorous randomized, double-blind, placebo-controlled trials evaluating interventions designed to prevent critical cardiovascular endpoints such as cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization. Through participation in large-scale multicenter studies, Cortex Study Center contributes valuable data to the development of preventive strategies for high-risk populations before the onset of clinical cardiovascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novartis Pharma AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cortex Study Center
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Atogepant in Acute Migraine Treatment: A Randomized, Double-Blind, Placebo-Controlled Study | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2023-09-04 | 2025-03-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.